Viking Therapeutics Other Long-Term Assets 2014-2024 | VKTX

Viking Therapeutics other long-term assets for the quarter ending September 30, 2024 were $0.000B, a 39.39% increase year-over-year.

  • Viking Therapeutics other long-term assets for 2023 were $0B, a 0% decline from 2022.
  • Viking Therapeutics other long-term assets for 2022 were $0B, a 0% decline from 2021.
  • Viking Therapeutics other long-term assets for 2021 were $0B, a 13.79% increase from 2020.

Viking Therapeutics Other Long-Term Assets 2014-2024 | VKTX

  • Viking Therapeutics other long-term assets for 2023 were $0B, a 0% decline from 2022.
  • Viking Therapeutics other long-term assets for 2022 were $0B, a 0% decline from 2021.
  • Viking Therapeutics other long-term assets for 2021 were $0B, a 13.79% increase from 2020.
Related Stocks
Company NameMarket
Cap
Amgen (AMGN)$171.5B
Vertex Pharmaceuticals (VRTX)$121.6B
Gilead Sciences (GILD)$111.4B
Bristol Myers Squibb (BMY)$110.2B
Regeneron Pharmaceuticals (REGN)$93B
CSL (CSLLY)$90B
GSK (GSK)$76.4B
Argenex SE (ARGX)$35.6B
Alnylam Pharmaceuticals (ALNY)$35.3B
BioNTech SE (BNTX)$26.5B
Biogen (BIIB)$25.3B
Illumina (ILMN)$23.9B
Moderna (MRNA)$21B
BeiGene (BGNE)$19.9B
Genmab (GMAB)$14.9B
Incyte (INCY)$14.7B
Exact Sciences (EXAS)$12.9B
BioMarin Pharmaceutical (BMRN)$12.7B
Vaxcyte (PCVX)$12B
Bio-Techne Corp (TECH)$11.9B
Sarepta Therapeutics (SRPT)$11.8B
Insmed (INSM)$11.7B
QIAGEN (QGEN)$9.8B
Exelixis (EXEL)$9.7B
Bio-Rad Laboratories (BIO.B)$9.3B
Revolution Medicines (RVMD)$9.2B
Intra-Cellular Therapies (ITCI)$9.2B
Roivant Sciences (ROIV)$8.6B
Legend Biotech (LEGN)$8.1B
Repligen (RGEN)$7.8B